Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA)
Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA)
复制标题
利奈唑胺治疗耐甲氧西林金黄色葡萄球菌（MRSA）引起的假体髋部感染
DOI：
10.1007/s101950070008
复制
发表时间：
2000
影响因子：
2.8
通讯作者：
D. Bassetti
中科院分区：
文献类型：
--
作者：
M. Bassetti;A. di Biagio;G. Cenderello;V. del Bono;A. Palermo;L. Molfetta;F. Pipino;D. Bassetti
Abstract Prosthetic joint infection is an infrequent but serious complication of total joint arthroplasty. Complete removal of all foreign material is essential, however when prosthesis removal is not possible or is contraindicated, suppressive antibiotic therapy with retention of the functioning hip arthroplasty may be considered. Linezolid, the first approved oxazolidinone, appears to be a promising new agent for the treatment of serious gram-positive infections. We report two cases of prosthetic hip infections with methicillin-resistant Staphylococcus aureus (MRSA) that were successfully treated with long courses of linezolid. This observation suggests that linezolid is a promising drug for the treatment of prosthetic joint infections due to MRSA or other gram-positive bacteria, particularly when other therapeutic approaches are not feasible or a long-term antibiotic therapy is required.
